AP983A - Freeze-dried composition of bone morphogenetic protein human MP52. - Google Patents

Freeze-dried composition of bone morphogenetic protein human MP52. Download PDF

Info

Publication number
AP983A
AP983A APAP/P/1999/001602A AP9901602A AP983A AP 983 A AP983 A AP 983A AP 9901602 A AP9901602 A AP 9901602A AP 983 A AP983 A AP 983A
Authority
AP
ARIPO
Prior art keywords
bone morphogenetic
morphogenetic factor
factor human
mannitol
composition
Prior art date
Application number
APAP/P/1999/001602A
Other languages
English (en)
Other versions
AP9901602A0 (en
Inventor
Hideki Ichikawa
Mitsuko Inagaki
Original Assignee
Biopharm Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biopharm Gmbh filed Critical Biopharm Gmbh
Publication of AP9901602A0 publication Critical patent/AP9901602A0/xx
Application granted granted Critical
Publication of AP983A publication Critical patent/AP983A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
APAP/P/1999/001602A 1997-01-30 1998-01-29 Freeze-dried composition of bone morphogenetic protein human MP52. AP983A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP1634997 1997-01-30
PCT/JP1998/000371 WO1998033514A1 (fr) 1997-01-30 1998-01-29 Composition lyophilisee de mp52 humaine de proteines morphogenetiques osseuses

Publications (2)

Publication Number Publication Date
AP9901602A0 AP9901602A0 (en) 1999-09-30
AP983A true AP983A (en) 2001-07-16

Family

ID=11913900

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/1999/001602A AP983A (en) 1997-01-30 1998-01-29 Freeze-dried composition of bone morphogenetic protein human MP52.

Country Status (22)

Country Link
EP (1) EP0972520B9 (da)
JP (1) JP4209948B2 (da)
KR (1) KR100548107B1 (da)
CN (1) CN1152712C (da)
AP (1) AP983A (da)
AT (1) ATE302021T1 (da)
AU (1) AU737595B2 (da)
BR (1) BR9807537B1 (da)
CA (1) CA2278546C (da)
DE (1) DE69831223T9 (da)
DK (1) DK0972520T3 (da)
EA (1) EA001579B1 (da)
ES (1) ES2244043T3 (da)
HU (1) HU226554B1 (da)
IL (2) IL130967A0 (da)
NO (1) NO322334B1 (da)
NZ (1) NZ336509A (da)
PL (1) PL189381B1 (da)
RS (1) RS49691B (da)
SI (1) SI0972520T1 (da)
TR (1) TR199901832T2 (da)
WO (1) WO1998033514A1 (da)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6281195B1 (en) † 1997-02-07 2001-08-28 Stryker Corporation Matrix-free osteogenic devices, implants and methods of use thereof
US20050053596A1 (en) * 2001-10-09 2005-03-10 Stringer Bradley Michael John Therapeutic biological product and method for formation of new vascularised bone
AU2002308204B9 (en) 2001-11-19 2008-06-12 Scil Technology Gmbh Device having osteoinductive and osteoconductive properties
DK1539261T3 (da) 2002-09-10 2006-08-07 Scil Technology Gmbh Metalimplantat belagt under nedsat oxygenkoncentration med osteoinduktiv protein
JP2007501223A (ja) * 2003-08-05 2007-01-25 フジ フォト フィルム ビー．ブイ． 安定剤としての組換え又は合成ゼラチンのワクチン中の使用
AU2004288854B2 (en) * 2003-11-10 2009-10-01 Arriva-Pharmaceuticals, Inc. Dry recombinant human alpha 1-antitrypsin formulation
DE602005022998D1 (de) 2004-03-10 2010-09-30 Scil Technology Gmbh Überzogene implantate, ihre herstellung und verwendung davon
US20160344677A1 (en) 2015-05-22 2016-11-24 Microsoft Technology Licensing, Llc Unified messaging platform for providing interactive semantic objects
US10360287B2 (en) 2015-05-22 2019-07-23 Microsoft Technology Licensing, Llc Unified messaging platform and interface for providing user callouts

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996033215A1 (fr) * 1995-04-19 1996-10-24 Hoechst Pharmaceuticals & Chemicals K.K. Proteine nouvelle et son procede de fabrication

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3273597D1 (en) * 1981-11-28 1986-11-06 Sunstar Kk Pharmaceutical composition containing interferon in stable state
US5037644A (en) * 1986-10-27 1991-08-06 Cetus Corporation Pharmaceutical compositions of recombinant interleukin-2 and formulation processes
JP3351525B2 (ja) * 1991-06-21 2002-11-25 ジェネティックス・インスティテュート・インコーポレイテッド 骨形成性蛋白医薬処方物
JP2966592B2 (ja) * 1991-07-20 1999-10-25 萩原 義秀 安定化されたヒトモノクローナル抗体製剤
CZ287715B6 (en) * 1992-02-12 2001-01-17 Bioph Biotech Entw Pharm Gmbh DNA sequence, recombinant DNA molecule containing thereof, process for preparing protein from the group of TGF-beta substances, pharmaceutical preparation containing such protein, antibody or fragment thereof and its use
CA2093836A1 (en) * 1992-04-24 1993-10-25 Wayne Gombotz Biodegradable tgf-.beta. delivery system for bone regeneration
DE4239877C1 (de) * 1992-11-27 1994-03-17 Boehringer Ingelheim Int Stabilisierte Superoxid-Dismutase (SOD)-Zusammensetzung
AU707796B2 (en) * 1995-03-21 1999-07-22 Merck Serono Sa HCG liquid formulations

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996033215A1 (fr) * 1995-04-19 1996-10-24 Hoechst Pharmaceuticals & Chemicals K.K. Proteine nouvelle et son procede de fabrication

Also Published As

Publication number Publication date
WO1998033514A1 (fr) 1998-08-06
AU5679198A (en) 1998-08-25
ES2244043T3 (es) 2005-12-01
IL130967A0 (en) 2001-01-28
BR9807537B1 (pt) 2009-01-13
HU226554B1 (en) 2009-03-30
EP0972520A4 (en) 2002-11-05
AU737595B2 (en) 2001-08-23
NZ336509A (en) 2001-03-30
SI0972520T1 (sl) 2006-02-28
CA2278546C (en) 2008-04-01
EP0972520A1 (en) 2000-01-19
HUP0002386A2 (hu) 2000-11-28
DE69831223T9 (de) 2006-12-07
NO993702D0 (no) 1999-07-29
EA199900694A1 (ru) 2000-04-24
CN1244127A (zh) 2000-02-09
YU34999A (sh) 2002-08-12
NO322334B1 (no) 2006-09-18
HUP0002386A3 (en) 2002-09-30
IL130967A (en) 2006-12-10
RS49691B (sr) 2007-12-31
EP0972520B9 (en) 2006-03-22
CA2278546A1 (en) 1998-08-06
BR9807537A (pt) 2000-03-21
PL189381B1 (pl) 2005-07-29
DE69831223T2 (de) 2006-02-16
DE69831223D1 (de) 2005-09-22
EP0972520B1 (en) 2005-08-17
EA001579B1 (ru) 2001-06-25
KR100548107B1 (ko) 2006-02-02
DK0972520T3 (da) 2005-12-19
PL334852A1 (en) 2000-03-27
JP4209948B2 (ja) 2009-01-14
KR20000070586A (ko) 2000-11-25
ATE302021T1 (de) 2005-09-15
NO993702L (no) 1999-09-29
AP9901602A0 (en) 1999-09-30
TR199901832T2 (xx) 1999-12-21
CN1152712C (zh) 2004-06-09

Similar Documents

Publication Publication Date Title
CA2139358C (en) Human growth hormone aqueous formulation
DE68918853T2 (de) Formulierung von menschlichen wachstumshormonen.
KR100942399B1 (ko) Ｅｇｆ 수용체에 대한 항체를 함유하는 동결건조된 제제
EP1174148A1 (en) Parenteral medicinal composition containing humanized monoclonal antibody fragment and method for stabilizing the same
HU202761B (en) Process for producing stabilized erythropoietin compositions
JPH08505610A (ja) 貯蔵安定性なｇ−ｃｓｆの水性薬理製剤
AU738413B2 (en) Human growth hormone-containing aqueous pharmaceutical composition
AP983A (en) Freeze-dried composition of bone morphogenetic protein human MP52.
US20220133633A1 (en) Pharmaceutical taci-fc fusion protein formulation
KR100377967B1 (ko) Hcg액상조성물
US5898030A (en) hGH containing pharmaceutical compositions
JPH01168624A (ja) 抗体の安定化
KR20040018458A (ko) Ｃｅｔｕｘｉｍａｂ 및 폴리옥시에틸렌 소르비탄 지방산에스테르를 포함하는 액형 제제
US20040132653A1 (en) Lyophilized composition of bone morphogenetic factor human MP52
CA1289071C (en) Pharmaceutical compositions for parenteral use containing a calcitonin as the active ingredient
MXPA99006784A (en) Freeze-dried composition of bone morphogenetic protein human mp52
RU2160605C2 (ru) Жидкие композиции, содержащие человеческий хорионический гонадотропин (hcg)
JPH01246226A (ja) 安定な修飾アスパラギナーゼ含有組成物
UA50811C2 (uk) Ліофілізована композиція морфогенетичного фактора кістки, спосіб одержання ліофілізованої композиції морфогенетичного фактора кістки
JP2005232177A (ja) Ｈｇｈ含有医薬組成物
US20160095904A1 (en) Stabilized liquid formulation
JPS62149623A (ja) 安定なｇｒｆ製剤
CA2215936A1 (en) Hcg liquid formulations